This makes a lot of sense. De-extincting an entire species will require breakthroughs in all kinds of areas: gene editing and sequencing, artificial wombs, and so on. Lamm wants all the technology Colossal develops to have potential applications—and paying customers—in the world of human health care. “That’s fundamental to our technology strategy,” he says.
The founder has a few other ideas for potential revenue streams. One is a way for scientists to rapidly analyze gene-edited cells and check that the edits work as expected. He’s also excited by some of the work that Colossal’s embryology team is working on. “We think this has massive applications across all IVF,” he says.
→ Continue reading at Wired - Science